ES3062687T3 - Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity - Google Patents

Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity

Info

Publication number
ES3062687T3
ES3062687T3 ES22724964T ES22724964T ES3062687T3 ES 3062687 T3 ES3062687 T3 ES 3062687T3 ES 22724964 T ES22724964 T ES 22724964T ES 22724964 T ES22724964 T ES 22724964T ES 3062687 T3 ES3062687 T3 ES 3062687T3
Authority
ES
Spain
Prior art keywords
formula
another embodiment
ring
alkyl
elements
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES22724964T
Other languages
English (en)
Spanish (es)
Inventor
Younggi Choi
Yuan Hu
Hoan Huynh
Brian Aquila
Brian Raymer
Ingo Mugge
James Woods
Lewis Pennington
Jörg Bentzien
Jonathan Lehmann
Michael Hale
Roman Valiulin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Application granted granted Critical
Publication of ES3062687T3 publication Critical patent/ES3062687T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES22724964T 2021-04-26 2022-04-25 Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity Active ES3062687T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163179616P 2021-04-26 2021-04-26
PCT/US2022/026144 WO2022232025A1 (en) 2021-04-26 2022-04-25 Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity

Publications (1)

Publication Number Publication Date
ES3062687T3 true ES3062687T3 (en) 2026-04-13

Family

ID=81750587

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22724964T Active ES3062687T3 (en) 2021-04-26 2022-04-25 Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity

Country Status (8)

Country Link
US (1) US20240124485A1 (enExample)
EP (1) EP4329877B1 (enExample)
JP (1) JP7862437B2 (enExample)
CN (1) CN117440955A (enExample)
AU (1) AU2022267220A1 (enExample)
CA (1) CA3215210A1 (enExample)
ES (1) ES3062687T3 (enExample)
WO (1) WO2022232025A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120584118A (zh) * 2022-11-23 2025-09-02 沃泰克斯药物股份有限公司 食欲素受体2的经取代的大环胺调节剂
JP2026506356A (ja) 2023-01-31 2026-02-24 ジャズ ファーマシューティカルズ アイルランド リミテッド 大環状オレキシン受容体アゴニスト及びその使用
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン２受容体アゴニスト
WO2025096445A1 (en) 2023-10-30 2025-05-08 Alkermes, Inc. Synthesis of intermediates for the preparation of macrocyclic compounds
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207610B1 (pl) * 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
WO2007144394A2 (en) * 2006-06-16 2007-12-21 High Point Pharmaceuticals, Llc. Pharmaceutical use of substituted piperidine carboxamides
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
MX2011004551A (es) * 2008-10-30 2011-05-25 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida.
US20100152103A1 (en) * 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
SG11201806429PA (en) * 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
JP6957598B2 (ja) * 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EA039459B1 (ru) * 2017-12-25 2022-01-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение в качестве средства для лечения заболеваний, связанных с рецептором орексина 2 типа
EP3816154B1 (en) * 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
EP4010314B1 (en) * 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
KR20260083444A (ko) * 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment

Also Published As

Publication number Publication date
EP4329877C0 (en) 2026-02-04
EP4329877B1 (en) 2026-02-04
US20240124485A1 (en) 2024-04-18
JP2024516633A (ja) 2024-04-16
WO2022232025A1 (en) 2022-11-03
AU2022267220A1 (en) 2023-10-19
CN117440955A (zh) 2024-01-23
JP7862437B2 (ja) 2026-05-19
EP4329877A1 (en) 2024-03-06
CA3215210A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
EP4329877B1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
ES3041424T3 (en) Substituted macrocyclic compounds and related methods of treatment
US12006330B2 (en) Substituted macrocyclic compounds and related methods of treatment
ES3012114T3 (en) Substituted piperidino compounds and related methods of treatment
EP4347046A1 (en) Substituted fused bicyclic macrocyclic compounds and related methods of treatment
ES3057101T3 (en) Substituted carbamate macrocyclic compounds and related methods of treatment
AU2023288422A1 (en) Substituted fused bicyclic compounds and related methods of treatment
JP2025521503A (ja) 置換ピロリジニル及びピペリジニル化合物並びに関連する治療方法
HK40108225B (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40108225A (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
HK40106635B (en) Substituted carbamate macrocyclic compounds and related methods of treatment
HK40106635A (en) Substituted carbamate macrocyclic compounds and related methods of treatment
HK40099265A (en) Substituted piperidino compounds and related methods of treatment
HK40099265B (en) Substituted piperidino compounds and related methods of treatment